ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

FKC876

A development code. Also written as “FKC876 injection”.

Its studies are led by Fosun Pharma.

Furthest: early phase 1, since May 19, 20261 company-led study, 1 open or runningNext primary completion: Nov 30, 2026 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningearly phase 1since May 19, 2026May 19, 2026Nov 30, 2026early phase 1 · NCT07606937

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2026First study: early phase 1 study in RecurrenceFirst studyNCT07606937 · 12 planned · China

Ahead

  1. Nov 30, 2026Primary completion: early phase 1 study in RecurrenceNCT07606937

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07606937Recurrence · ChinaEarly 1RecruitingNov 30, 202612

How it is read

Names in the registry

  • “FKC876 injection”, 1 entry

Codes read as this program: FKC876.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.